Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (227)	3/23/1999 1:41:00 AM
From: Sam Lee	Read Replies (1) \| Respond to of 320

Yes and I think back then the expectation was $30 based on the same pipeline of drugs,but 1/3 fewer shares outstanding. I am holding my stock. This is now a viable company with plenty of cash and milestones to get through this year and next. What happened, as I understand it, was that the nyotran patient accrual got bogged down for a long time and the company got closer to the edge than intended. IMHO. The whole process fell about a year behind and the stock lost coverage and momentum. But the story is still a good one. If this stock hits $13 b/t now and the end of 2000 then I will be richly rewarded. I think the worst case scenario is about $7-8 during the same time. IMHO. I expect only sporadic posts and those will be mainly as milestones are reached. But we investors are here and waiting patiently.